Shares of EXACT Sciences Corporation (NASDAQ:EXAS) ended Tuesday session in red amid volatile trading. The shares closed down -0.10 points or -0.51% at $19.34 with 2.22 million shares getting traded. Post opening the session at $19.46, the shares hit an intraday low of $19.16 and an intraday high of $19.90 and the price vacillated in this range throughout the day. The company has a market cap of $1.94 billion and the numbers of outstanding shares have been calculated to be 106.77 million shares.
EXACT Sciences Corporation (EXAS) on Sept. 16, 2016 announced that, in support of the Company’s continued growth plans, it granted restricted stock units covering a total of 24,119 shares of common stock to 18 recently hired non-executive employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were granted as an inducement material to the recently hired employees entering into employment with the Company in accordance with NASDAQ Marketplace Rule 5635(c)(4). The Company is making this announcement as required by NASDAQ rules.
Shares of AbbVie Inc (NYSE:ABBV) ended Tuesday session in green amid volatile trading. The shares closed up +0.50 points or 0.78% at $64.57 with 4.36 million shares getting traded. Post opening the session at $63.95, the shares hit an intraday low of $63.69 and an intraday high of $64.75 and the price vacillated in this range throughout the day. The company has a market cap of $104.99 billion and the numbers of outstanding shares have been calculated to be 1.63 billion shares.
AbbVie Inc (ABBV) on Sept. 26, 2016 announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ibrutinib (IMBRUVICA®) to treat patients with marginal zone lymphoma (MZL). MZL is a slow-growing form of non-Hodgkin’s lymphoma. The Company’s sNDA submission is based on data from a multi-center, open-label Phase II PCYC-1121-CA trial assessing ibrutinib as a single-agent treatment for MZL. If approved, MZL will be the fifth unique type of blood cancer indication for IMBRUVICA. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
“We continue to explore the use of ibrutinib in non-Hodgkin’s lymphoma, including marginal zone lymphoma and its three sub-types, given its unique mechanism of action and ability to target the B-cell receptor pathway,” said Darrin Beaupre, M.D., Ph.D., Head of Early Development and Immunotherapy at Pharmacyclics. “MZL in its advanced stages is currently an incurable form of hematologic cancer and new treatment options are needed. We look forward to working with the FDA and our partners at Janssen to bring this promising treatment to patients with MZL.”